Hologic Ranked #1 for Mammography System Performance and Customer Satisfaction for 10th Consecutive Year
Hologic, Inc. (NASDAQ: HOLX) has been awarded three IMV ServiceTrak™ Awards for Mammography during RSNA 2022, marking its 10th consecutive year receiving top honors for service, customer satisfaction, and system performance. The company is recognized for its Genius® 3D Mammography™ exam, which is FDA-approved for enhanced detection of breast cancer. Hologic's SureCare® Service offers comprehensive support to customers, ensuring optimal system performance. This recognition highlights Hologic's commitment to excellence in women's health technology.
- Received three IMV ServiceTrak™ Awards for Mammography, including Best Service and Best Customer Satisfaction.
- 10th consecutive year ranked top in Mammography System Performance.
- Genius® 3D Mammography™ exam shows enhanced detection of 20%-65% more invasive breast cancers.
- None.
Global Leader in Women’s Health Recognized with Three IMV ServiceTrak™ Awards for Mammography During RSNA 2022
“We are thrilled to win the IMV Award for a 10th year and need to acknowledge our outstanding service team that has kept us on top of the IMV leaderboard,” said
Hologic is the company behind the Genius® 3D Mammography™ exam, the only mammogram approved by the FDA as superior to conventional mammography for all women, including those with dense breasts.1 It also detects
SureCare® Service from Hologic offers a variety of service plans designed to help customers get the most out of their systems. SureCare plan options include maximum uptime guarantees, predictive analytics* to address equipment issues before they occur and state-of-the-art connectivity to provide real-time insights on optimizing business and clinical outcomes.
Hologic’s strong team of veteran service and support experts includes factory-trained field engineers solely focused on servicing Hologic systems and highly qualified clinical applications specialists who assist new users along every step of setup, on-site training and beyond.
“We are honored to receive this recognition from IMV once again as it underscores the team’s partnership with our customers,” said
To learn more about SureCare Service from Hologic, visit www.Hologic.com/SureCare-Service.
About
The company also champions women through the Hologic Global Women’s Health Index, which provides a science-backed data roadmap for improving women’s well-being, and Project Health Equality, which elevates awareness, research insights and access to quality care for underserved women.
Forward-Looking Statements
This news release may contain forward-looking information that involves risks and uncertainties, including statements about the use of Hologic products. There can be no assurance these products will achieve the benefits described herein or that such benefits will be replicated in any particular manner with respect to an individual patient, as the actual effect of the use of the products can only be determined on a case-by-case basis. In addition, there can be no assurance that these products will be commercially successful or achieve any expected level of sales. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such data or statements are based.
This information is not intended as a product solicitation or promotion where such activities are prohibited. For specific information on what products are available for sale in a particular country, please contact a local Hologic sales representative or write to womenshealth@hologic.com.
SOURCE:
_________________________
* Available on select systems
1 FDA Approvals P080003, P080003/S001, P080003/S004, P080003/S005
2 Results from Friedewald, SM, et al. "Breast cancer screening using tomosynthesis in combination with digital mammography." JAMA 311.24 (2014): 2499-2507; a multi-site (13), non-randomized, historical control study of 454,000 screening mammograms investigating the initial impact the introduction of the Hologic Selenia® Dimensions ® on screening outcomes. Individual results may vary. The study found an average
View source version on businesswire.com: https://www.businesswire.com/news/home/20221201005352/en/
Media Contact:
Vice President,
(+1) 508.263.8764
jane.mazur@hologic.com
Investor Contact:
Vice President, Investor Relations
(+1) 858.410.8514
ryan.simon@hologic.com
Source:
FAQ
What awards did Hologic, Inc. receive for Mammography in 2022?
How long has Hologic been recognized for its Mammography services?
What is the significance of Hologic's Genius® 3D Mammography™ exam?
What is SureCare® Service offered by Hologic?